📜 What This Document Is 📰

This document is a Post-Effective Amendment No. 3 to a Form S-1 Registration Statement. In simple terms, an S-1 is what a company files with the SEC when it is preparing to sell its stock to the public (an Initial Public Offering, or IPO). This amendment means the company is updating its foundational document to include the most recent annual report data.

👉 Why it matters: Since this is a registration statement, the company is preparing for significant capital events. However, the content is heavily focused on describing the risks and the technology—which is typical for pre-IPO biotech companies—rather than reporting current profits.

🕷️ What The Company Does 🧬

Kraig Biocraft Laboratories, Inc. is a Wyoming corporation that works in the highly specialized field of biotechnology. In simple terms, they are harnessing the natural properties of spider silk to create next-generation industrial fibers. They do this using genetic engineering, transforming common silkworms to produce the unique proteins found in spider silk.

👉 Key Focus: Their mission is to develop high-performance, bio-compatible, and biodegradable recombinant spider silk materials that can replace conventional silk and synthetic fibers worldwide.

✨ The Product Portfolio 🧵

The Company's products are based on spider silk, which is known for its superior physical characteristics, including incredible strength, resilience, and flexibility. They have developed several unique branded products that represent different stages of their technology.

• Monster Silk®: This was their first product, incorporating natural spider elasticity to make silk fibers more flexible and durable than traditional textiles.
• Dragon Silk™: This is the "next evolution," combining Monster Silk’s elasticity with enhanced strength. They claim samples have demonstrated strength beyond that of native spider silk, making it useful for performance apparel, durable workwear, and composites.
• Future Potential: They are continuing to develop new recombinant silks and proteins. Due to silk's natural biocompatible and biodegradable nature, they anticipate opportunities in the medical industry, such as manufacturing sutures, grafts, and implants.

🔬 Scientific Breakthrough & Operations 🚀

The core of KBLB’s value lies in its unique, advanced technology platform. They use genetically modified silkworms that are engineered to produce silk based on spider silk proteins. Their operational strategy is highly efficient and minimizes capital costs.

• Drop-in Replacement: Their technology is designed as a "direct drop-in replacement" for existing traditional silk manufacturing processes. This means existing silk operations can convert to use their silkworm technology without needing significant additional capital investment.
• Improved Platform: They developed a new technology platform (non-CRISPR Cas9 gene editing) that they claim is more advanced than their prior methods. Management believes this new approach will allow them to accelerate development and create materials that even surpass the capabilities of Dragon Silk.
• Scaling Operations: To scale up, they are expanding production in Vietnam, establishing a wholly owned subsidiary called Prodigy Silk Co. Ltd. This helps manage their supply chain and utilizes a distributed production model, mimicking how traditional silk is produced.

🤝 Strategic Partnerships & Growth 🌿

The Company is not operating in a vacuum; it is building its market acceptance through strategic agreements and collaborations. These partnerships are crucial for moving the products from the lab to the market.

• M the Movement by Kings Group: In January 2021, KBLB entered into an exclusive purchase agreement with M the Movement by Kings Group. This partnership includes establishing a jointly owned apparel and fashion brand headquartered in Singapore, focused on sales across the ASEAN region.
• Vietnamese Collaborators: They signed an agreement with the Vietnam Sericulture Association (VSA) and the Lam Dong Agro-Forestry Research & Experiment Center (LAREC). These partnerships are designed to enhance sericulture in Vietnam through the application of KBLB's silkworm technology.

💰 Financing & Equity Activity 💵

The filing details a significant financing event through a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., a Cayman Islands exempt limited partnership. This provides a major source of potential capital.

• SEPA Details: Under this agreement, the Company has the right to sell up to $10 million in aggregate gross proceeds worth of common stock to YA II PN, LTD.
• Commitment Shares: As part of the agreement, the Company initially issued 1,081,471 shares of Common Stock to the Investor (the "Commitment Shares").
• Use of Funds: While the Company does not receive proceeds from the shares sold by the Investor, they expect to use the net proceeds (up to $10 million) for general corporate purposes and working capital.

🚨 Major Financial and Operating Warnings ⚠️

The most critical takeaways from this document relate to the extreme level of risk and the company's current financial status, signaling that the company is in a pre-revenue, development phase.

• Zero Revenue: For both the fiscal years ended December 31, 2025, and December 31, 2024, the Company generated $0 in revenue.
  • 👉 Why it matters: This indicates that KBLB has not yet reached commercial revenue streams, making it extremely difficult to predict when or if they will ever become profitable.
• Going Concern Qualification: The report from the independent registered public accounting firm covering both 2025 and 2024 contained a going concern qualification. This means the auditors found "substantial doubt" regarding the Company's ability to continue operating, due to factors like working capital and shareholder deficit.
  • 👉 Why it matters: The company is dependent on raising capital (like the funds from the SEPA) to survive and continue its operations.
• Internal Controls: The Company reports that its internal control over financial reporting was not effective because of material weaknesses, specifically citing a lack of qualified resources for independent audit functions and ineffective segregation of duties.
  • 👉 Why it matters: These weaknesses suggest operational and reporting risks that could negatively impact investor confidence.

⚙️ Investor & Corporate Information ℹ️

This section provides essential details about the company's market status and key personnel.

• Stock Quote: KBLB’s Common Stock is quoted on the OTCQB under the ticker symbol “KBLB.”
• Outstanding Shares: As of April 20, 2026, there are 1,103,871,733 shares of Common Stock issued and outstanding.
• Founding Ownership: Kim Thompson, the founder and CEO, owns approximately 14.07% of the Common Stock and holds all 3 super voting Series A Preferred Stock shares, representing 36.45% of all voting rights.
• Management/Service Agent: Kim Thompson serves as both the CEO and the listed Agent for Service. Contact for the principal executive offices is 2723 South State St. Suite 150, Ann Arbor, Michigan 48104, with a phone number of (734) 619-8066.

🚧 Comprehensive Risk Factors Summary 🌪️

The filing dedicates significant space to risks, highlighting that investment in the company is "highly speculative and risky." These risks span market, scientific, and regulatory domains.

• Technology & Market Acceptance: The company's success relies on scientific research that has not yet demonstrated commercial viability. The market acceptance of their novel fibers is uncertain, and their efforts must contend with potential failure to generate significant revenues.
• GMO & Ethical Concerns: Products are based on Genetically Modified Organisms (GMOs). This exposes them to potential product liability claims, public opinion, and intense legal/ethical opposition. Opponents can initiate regulatory challenges or labeling campaigns that could severely limit their market.
• Competition & Resources: The industry has low barriers to entry, meaning they face increased competition from larger companies with greater financial resources.
• External Events: The business is highly vulnerable to global disruptions, including health epidemics (like COVID-19), natural disasters, wars, or trade restrictions, which can disrupt the supply chain or access to capital.

💡 Key Takeaways and Looking Ahead 🎯

Because this is a post-effective amendment, it serves primarily as an update on the prospectus terms and risks rather than a financial report.

• Liquidity/Sale Mechanics: The Selling Stockholder (YA II PN, Ltd.) has the freedom to determine when and how it will dispose of the registered common stock.
• Projected Growth: The company expects to use the net proceeds from the SEPA for working capital and general corporate purposes.
• Primary Goal: The immediate focus is on developing and scaling the specialized silkworm production system in Vietnam to increase robustness and cocoon size.

---

🧠 The Analogy

Investing in Kraig Biocraft Laboratories is like funding a futuristic, unproven deep-sea submersible. The technology (spider silk) is revolutionary and potentially incredible, but it exists entirely in the engineering phase. You've seen the beautiful, high-tech blueprints (the patents and lab reports), and you know the potential power source (the funding from the SEPA). However, the submersible has never truly been taken into the deep ocean; the engineers haven't generated a single dollar of revenue from it yet. The success hinges entirely on successfully navigating extreme, unpredictable unknowns: manufacturing reliability, hostile competition, and overcoming massive, unproven market resistance.

🧩 Final Takeaway

KBLB is a high-risk, pre-revenue biotech company dependent on venture capital to transition its innovative, genetically-engineered spider silk technology into a commercial reality. The immediate financial picture shows zero revenue, a pending "going concern" warning, and a complete reliance on future capital raises from strategic investors and its own product development.